Cell-based phenotypic drug screening identifies luteolin as candidate therapeutic for nephropathic cystinosis

Ester de Leo, Mohamed A. Elmonem, Sante Princiero Berlingerio, Marine Berquez, Beatrice Paola Festa, Roberto Raso, Francesco Bellomo, Tobias Starborg, Manoe Jacoba Janssen, Zeinab Abbaszadeh, Sara Cairoli, Bianca Maria Goffredo, Rosalinde Masereeuw, Olivier Devuyst, Martin Lowe, Elena Levtchenko, Alessandro Luciani, Francesco Emma, Laura Rita Rega

Research output: Contribution to journalArticlepeer-review

Abstract

Background Mutations in the gene that encodes the lysosomal cystine transporter cystinosin cause the lysosomal storage disease cystinosis. Defective cystine transport leads to intralysosomal accumulation and crystallization of cystine. The most severe phenotype, nephropathic cystinosis, manifests during the first months of life, as renal Fanconi syndrome. The cystine-depleting agent cysteamine significantly delays symptoms, but it cannot prevent progression to ESKD and does not treat Fanconi syndrome. This suggests the involvement of pathways in nephropathic cystinosis that are unrelated to lysosomal cystine accumulation. Recent data indicate that one such potential pathway, lysosome-mediated degradation of autophagy cargoes, is compromised in cystinosis. Methods To identify drugs that reduce levels of the autophagy-related protein p62/SQSTM1 in cystinotic proximal tubular epithelial cells, we performed a high-throughput screening on the basis of an in-cell ELISA assay. We then tested a promising candidate in cells derived from patients with, and mouse models of, cystinosis, and in preclinical studies in cystinotic zebrafish. Results Of 46 compounds identified as reducing p62/SQSTM1 levels in cystinotic cells, we selected luteolin on the basis of its efficacy, safety profile, and similarity to genistein, which we previously showed to ameliorate other lysosomal abnormalities of cystinotic cells. Our data show that luteolin improves the autophagy-lysosome degradative pathway, is a powerful antioxidant, and has antiapoptotic properties. Moreover, luteolin stimulates endocytosis and improves the expression of the endocytic receptor megalin. Conclusions Our data show that luteolin improves defective pathways of cystinosis and has a good safety profile, and thus has potential as a treatment for nephropathic cystinosis and other renal lysosomal storage diseases.

Original languageEnglish
Pages (from-to)1522-1537
Number of pages16
JournalJournal of the American Society of Nephrology
Volume31
Issue number7
DOIs
Publication statusPublished - Jul 2020

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Cell-based phenotypic drug screening identifies luteolin as candidate therapeutic for nephropathic cystinosis'. Together they form a unique fingerprint.

Cite this